HNF to host an educational CMT symposium at AANEM’s Annual Conference October 10-13th in Washington, D.C.
True Reply and HNF have collaborated to enhance patient focused research and knowledge of what matters most to patients living with CMT.
StarWise Therapeutics LLC & HNF join forces to expedite the advancement of a new drug entity to the clinic for the treatment of CMT2A.
Enrollment and treatment are ongoing in Part 1 of the Phase 2 trial of ACE-083 in patients with CMT disease.
Learn how this CMT1A patient uses the AlterG treadmill to manage her CMT symptoms.